In a report released on March 2, David Risinger from Leerink Partners maintained a Hold rating on Amgen (AMGN – Research Report). The company’s ...

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the second quarter of 2025. The dividend will be paid on June 6, 2025, to all stockholders of ...

Amgen (AMGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...

Amgen and AstraZeneca have reported complete outcomes from the registrational Phase III WAYPOINT trial of Tezspire ...

U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further ...

The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...

We recently compiled a list of the 18 AI News and Ratings Making Waves on Wall Street. In this article, we are going to take ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

La La Anthony is partnering with Amgen to raise awareness and support those struggling with plaque psoriasis. The ...